CNCMTa Multi-center, Prospective, Single-arm Study
Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Cadonilimab in neoadjuvant chemotherapy and maintenance therapy for high-risk advanced cervical cancer receiving concurrent chemoradiotherapy
Phase:
NA
Details
Lead Sponsor:
Hubei Cancer Hospital
Collaborators:
Akeso Pharmaceuticals, Inc. Yichang Central People's Hospital